translating data to therapeutics
Our inherited genetic makeup shapes who we are, and it also contributes to the risk of disease throughout our lifetimes. Some genetic variants can increase the risk of certain diseases, while others may provide protection from disease.
The availability of longitudinal genetic and clinical data across millions of individuals around the globe, as well as new technology, cellular engineering and computational tools, have made it practical to identify variations in genes associated with disease, and study how those variations may alter the course of a disease. If we can understand how specific genetic variants protect against a disease, we may be able to mimic those effects and address the specific drivers of that disease, thereby changing outcomes for patients.
Compass™, our end-to-end platform, was purpose-built to capitalize on these advancements in an expedited fashion and is intended to produce a steady stream of targeted medicines for patients. Variant functionalization—looking not just at genetic variation but at the way that genetic variants impact proteins and disease course—is a critical piece of our process that in our view has not yet been fully harnessed in the fields of drug discovery and development. We believe that identifying the right variant in a sea of genetic information, mimicking its beneficial effects, and using these insights to identify those patients most likely to benefit, will translate into life-changing therapies for patients.